KENG TARQALGAN DORIGA CHIDAMLI OʻPKA SILINING MIKROBIOLOGIK XUSUSIYATLARI
##article.subject##:
mikrobiologik xususiyatlar, dori-darmonlarga chidamlilik, oʻpka sili##article.abstract##
Oʻpka silida bakteriyalarni koʻp miqdorda ajratilishi oʻpka toʻqimasidagi kavernoz oʻzgarishlarni va bakterial populyatsiyaning zichligini aks ettiruvchi bilvosita koʻrsatkich hisoblanadi. Keng tarqalgan dori-darmonlarga chidamli (XDR) oʻpka sili bilan kasallangan 135 bemor prospektiv ravishda tekshirildi. Tadqiqotga 18 yoshdan 65 yoshgacha boʻlgan 68 nafar erkak (45,8%) va 147 nafar ayol (67%) kiritildi. Oldindan davolangan bemorlar guruhida oʻpka XDR-silining bakteriologik xususiyatlari koʻpgina parametrlar boʻyicha sezilarli darajada aniqroq edi.
Библиографические ссылки
Abdullaev, R.Yu. Hepatotoxic reactions in the treatment of newly diagnosed patients with pulmonary tuberculosis with multidrug–resistant pathogen / R. Yu. Abdullaev, O. G. Komissarova, E. S. Chumakova [et al.] // Tuberculosis and lung diseases. – 2019. – Vol. 97. – No. 7. - pp. 21-27. (In Russian)
Baranova, O.N. Pulmonary tuberculosis with multidrug–resistant pathogen // Notes of a scientist. – 2015. - No. 6-1. – pp. 19-21. (In Russian)
Kuzmina, N.V. The course and effectiveness of treatment of tuberculosis with multiple and broad drug resistance // Fundamental and applied problems of human health in the North: A collection of materials of the V All-Russian Scientific and practical conference, Surgut, October 27, 2020. Surgut: Surgut State University, 2020. pp. 82-88. (In Russian)
Kranzer, K. New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? // Am J Respir Crit Care Med. - 2019. - Apr 26. [Epub ahead of print].
Vjecha, M.J. Accelerating the development of therapeutic strategies for drug‐resistant tuberculosis // Nat Rev Drug Discov. - 2018.-Vol.17(9). - P.607–608.
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2020.
Zhao, Y. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study // Clin Infect Dis 2018.
